We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
NeoMatrix Therapeutics announced positive topline data from its Phase 1 clinical trial of NMT-cP12, its lead candidate for the treatment of severe burns.